Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma

NCT00019682 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

185

Enrollment

NIH

Sponsor class

Conditions

Recurrent Melanoma
Stage IIIA Skin Melanoma
Stage IIIB Skin Melanoma
Stage IIIC Skin Melanoma
Stage IV Skin Melanoma

Interventions

BIOLOGICAL: Aldesleukin
BIOLOGICAL: gp100 Antigen
DRUG: Montanide ISA 51 VG
OTHER: Quality-of-Life Assessment
OTHER: Questionnaire Administration
OTHER: Laboratory Biomarker Analysis

Sponsor

National Cancer Institute (NCI)